Celea Therapeutics

#Celea Therapeutics #Idiopathic pulmonary fibrosis #Lung disease #PureTech #Respiratory

Celea Therapeutics launches into respiratory disease space

PureTech Health has announced the launch of a new founded entity Celea Therapeutics to deliver therapies for serious respiratory diseases.   Its lead programme, deupirfenidone (LYT-100), is a Phase III-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for the treatment of… Read More

#Business & Investment #News